MRNA — Moderna, Inc.

Summary of MRNA Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $700 million, with $300 million from the U.S. and $400 million from international markets.
• Full Year 2025 Revenue: $1.9 billion, primarily from COVID vaccine sales (Spikevax and MNEXT Spike) and approximately $100 million from other sources.
• Operating Expenses: Decreased by 30% year-over-year to $2.2 billion.
• Net Loss: $2.8 billion for the year, an improvement from a $3.6 billion loss in 2024. Loss per share was $7.26, down from $9.28.
• Cash and Investments: Ended 2025 with $8.1 billion, down from $9.5 billion in 2024, primarily due to operating losses but better than previous guidance.

2. Strategic Updates and Business Highlights

• Product Portfolio: Three products on the market: Spikevax, MNEXT Spike (which became the leading product in the U.S.), and Emresvia (RSV vaccine).
• Regulatory Developments: MNEXT Spike was approved in the U.S. in 2025. The flu vaccine mRNA-1010 is under review in Europe, Canada, and Australia, but received a refusal to file letter from the U.S. FDA.
• Commercial Agreements: New partnerships include a global commercialization agreement with Recordati for a rare disease candidate and a five-year strategic agreement with the Mexican government for respiratory vaccine supply.
• Pipeline Progress: Completed enrollment in multiple late-stage oncology studies and reported positive five-year phase 2 data for the individualized cancer therapy INT.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Expected growth of up to 10%, primarily driven by international markets and the second year of MNEXT Spike's launch.
• Cost Projections: Anticipated cost of sales around $900 million, with R&D expenses projected at $3 billion, and SG&A expenses remaining flat at $1 billion.
• Cash Guidance: Expected to end 2026 with $5.5 to $6 billion in cash and investments, without additional draws from the credit facility.

4. Bad News, Challenges, or Points of Concern

• Regulatory Uncertainty: The refusal to file letter from the FDA regarding mRNA-1010 raises concerns about the regulatory environment and its impact on future product approvals.
• Market Demand Decline: Overall COVID vaccine market demand has decreased year-over-year, which may affect future revenue.
• Cash Flow Risks: Despite a strong cash position, ongoing operating losses and reliance on successful product launches and approvals create financial risks.

5. Notable Q&A Insights

• Flu Vaccine Regulatory Path: The company is awaiting feedback from a Type A meeting with the FDA to clarify the path forward for mRNA-1010 in the U.S.
• INT Program Confidence: The phase 2 results for adjuvant melanoma show strong potential, with a focus on achieving compelling hazard ratios for future registrational studies.
• Norovirus Vaccine Expectations: The company is optimistic about its phase 3 trial results, emphasizing the differentiated approach of targeting older adults rather than children.
• Market Strategy in Europe: MNEXT Spike is expected to capture significant market share in Europe, with preparations for competitive pricing and marketing strategies underway.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Moderna's performance and outlook as of Q4 2025.